Search PubMed⌕ Search

Biomedical subjects

C Moore

Publications and source records attributed to C Moore.

At least 271 records · Page 15Linked to original sources
PubMed1986

Bladder base dosage in patients undergoing intracavitary therapy.

The maximum dose rate being delivered to the base of the bladder during intracavitary therapy was assessed in 20 patients by CAT scanning during treatment. This value was compared with the I.C.R.U. bladder reference point dose rate calculated from lateral radiographs taken after insertion. The ratio of the maximum bladder base dose rate to the I.C.R.U. reference dose rate varied from 1.01 to 3.59. In ten patients the maximum bladder dose rate was not in the midline. Re-examination of five patients revealed significant changes in bladder base dose rate in two due to changes in applicator positioning and packing. The bladder base dose rate on the vertical plane through the middle of the vaginal ovoids was within +/- 25% of the maximum bladder base dose rate in 22/25 examinations.

Adult↗
PubMed1986

Protracted low-dose cisplatin infusion in advanced colorectal cancer.

Protracted, 24-hour, continuous-infusion cisplatin at a dose rate of 5 mg/m2/day was administered to 25 patients with advanced measurable colorectal cancer. All patients had previously received 5-FU administered on the same schedule. Sixteen patients received the infusion for greater than or equal to 14 days and were considered evaluable for response assessment. No patient achieved a response.

Ambulatory Care↗
PubMed1985

Multidisciplinary pretreatment cancer planning.

One can estimate that 60% or more of cancer patients stand to benefit from the multidisciplinary treatment of cancer. Different treatments given in sequence mean real benefit in terms of absolute cure or length of disease-free life for many. While the details of treatment techniques can usually be worked out for each patient in expert fashion, the process of planning to fit the three main modalities together into a single plan presents complex problems. To obtain optimum results someone must assemble and coordinate the opinions of the oncologists who are consulted in each case; and someone must do it before treatment begins. Benefit is significantly reduced if the planning process is delayed until recurrence occurs. Those who act as primary physicians in caring for cancer patients have a newly defined major role to play: they must select the oncology team, coordinate the various opinions, and continue to supervise the course of the cancer throughout in order that the patients receive the best care. When a physician prepares for, and accepts, this role of leader-coordinator, and outlines in broad general terms a properly integrated plan from the first, details of therapy fall easily into place.

Cancer Care Facilities↗
PubMed1985

Protection against gram-negative bacteremia and endotoxemia with human monoclonal IgM antibodies.

Hybridomas producing human monoclonal IgM antibodies (mAbs) against bacterial lipopolysaccharide (LPS) were generated by fusion of B lymphocytes from sensitized human spleen with heteromyeloma cells. The splenocytes were from patients undergoing splenectomy during staging for Hodgkin disease after vaccination with the J5 mutant of Escherichia coli, which is deficient in O antigenic side chains. This deficiency exposes the core oligosaccharide, common to LPS of all Gram-negative bacteria. The mAbs cross-reacted strongly with endotoxins from a wide range of unrelated species of Gram-negative bacteria. The mAbs also gave strong protection against LPS in the dermal Shwartzman reaction and against lethal Gram-negative bacteremia in mice. These findings indicate that monoclonal IgM against LPS endotoxin can neutralize its toxicity in vivo and might be valuable for treatment of patients with Gram-negative bacteremia. Analysis of one of the hybridoma clones, A6(H4C5), showed that the IgM mAb is directed against the covalently bound lipid A, which represents the most conservative and least variable structural element of LPS.

Animals↗
PubMed1985

Complications and management of implanted venous access catheters.

A totally implanted subclavian venous access system composed of a reservoir and silastic catheter was employed in 92 patients receiving infusion chemotherapy and/or hyperalimentation. The major catheter complication was subclavian or jugular vein thrombosis observed in 15 patients (16%). Thrombosis was observed in the ipsilateral subclavian or jugular vein surrounding the catheter without restricting function, except in two patients with thrombosis in the vein at the end of the catheter. Prophylaxis with low-dose Coumadin was effective in preventing thrombosis in high-risk patients as defined by a history of prior thrombosis. Streptokinase and/or heparin relieved the signs and symptoms of thrombosis, but clot dissolution or reversal of collateral flow was not observed. Explantation of the catheter was not necessary in all patients in that embolic complications of the thrombosis were not observed, and the system was retained and functioned in five patients in spite of the presence of thrombosis around the catheter. Other complications of the implanted system include "pocket" infection, catheter migration, and occlusion. Most complications may be managed without obligate catheter removal.

Anti-Bacterial Agents↗
PubMed1985

Total counts of antral gastrin cells: a simple direct method.

A simple technique has been developed to quantitate the gastrin cells (G-cells) from the pyloric antrum of the rat. The antrum was digested in pronase to suspend the epithelial cells. This cell suspension was counted and pelleted. The pellet was embedded in paraffin, sectioned, then labeled using the indirect immunofluorescence technique specific for gastrin. The percentage of G-cells was determined from photographs of fluorescing sections and total G-cell numbers were determined by relating these data to total epithelial cell counts. In 14 rats the average G-cell population totaled 1.03 +/- 0.21 X 10(5) G-cells/antrum. The technique is simple, time-saving and avoids the uncertainties inherent in previous procedures for the estimation of G-cell numbers.

Animals↗
PubMed1983

Mapping restriction sites on large DNAs by electron microscopy.

We have developed a novel technique to map restriction sites on large duplex DNAs by electron microscopy. In this method, the sample DNA is first cut with a restriction enzyme. The resulting fragments are briefly digested with Escherichia coli exonuclease III, and treated with wheat germ RNA polymerase II to fill-in with RNA the resulting gaps. These small RNAs, complementary to sequences immediately adjacent to either side of the restriction site, are isolated from the DNA template and R-looped to the full-length DNA. When this material is prepared by the formamide-cytochrome spreading technique, small bubbles are visible wherever there is a restriction site on the DNA. Improved methods of mapping are outlined.

Bacteriophage lambda↗
PubMed1982

Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease.

Multiple molecular forms of beta-glucocerebrosidase that permit discrimination between neurologic and non-neurologic phenotypes of Gaucher disease have been identified radioimmunologically in fibroblasts and human brain tissue. In normal human fibroblasts these forms have been shown by NaDodSO4/polyacrylamide gel electrophoresis to have apparent Mr of 63,000 (form A1), 61,000 (form A2), and 56,000 (form B). The Mr 63,000 form may be a precursor of the Mr 56,000 form. Non-neurologic Gaucher disease (type 1) fibroblasts and normal brain tissue are characteristic in that they contain only one major immunoreactive protein, the Mr 56,000 form. In contrast, fibroblast extracts and brain tissue from neurologic Gaucher disease phenotypes contain only the higher molecular weight forms A1 and A2. These data and the low residual activity of the enzyme in all the variants of Gaucher disease suggest that the mutations of beta-glucocerebrosidase are allelic and involve the active site.

Brain↗
PubMed1981

Analysis of breast cancer screening in women younger than 50 years.

The five-year screening experience for 10,128 asymptomatic women whose conditions were evaluated at the Louisville Breast Cancer Detection Demonstration Project disclosed 163 breast carcinomas in women aged 35 to 74 years. Thirty-four percent of patients with proved carcinoma were younger than 50 years; 31% with infiltrating carcinoma had axillary metastases at the time of diagnosis. In younger patients, carcinomas disclosed at intervals between scheduled screenings were more commonly metatastic. Minimal breast cancer was more prevalent in the screened population (29%) than the unscreened population (less than 5%), and appeared with similar frequency in screenees of each age category. Screening women younger than 50 years allow earlier diagnosis and treatment of breast cancer in a favorable stage that is comparable with that noted in the older screenees.

Adult↗